Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Participants

NCT01520142 ↗

Phase 1 Completed 19 enrolled Janssen Research & Development, LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the anti-inflammatory properties of JNJ-26528398 using an intravenous (IV) endotoxin-induced model of acute, transient inflammation.

Timeline

Start: 2011-11
Primary completion: 2012-04
Completion: 2012-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-26528398	Unknown	3 mg	Oral

Indications

No indication recorded.